Tag: $Eli Lilly

Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.

Eli Lilly said Amazon Pharmacy will help deliver certain prescription drugs, including the popular weight loss treatment Zepbound, directly to patients’ homes through the drugmaker’s new direct-to-consumer website. 

Eli Lilly reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro.

Eli Lilly and Co on Thursday launched a website to help people with obesity get prescriptions through telehealth providers and provide home delivery of its weight-loss medicines.

Shares of Eli Lilly & Co. rose 0.67% in premarket trading Friday after drug giant announced plans to spend $2.5 billion to build a new manufacturing facility in Germany.

Eli Lilly reported third-quarter revenue and adjusted earnings that topped expectations, lifted by $1.4 billion in sales from its blockbuster diabetes drug Mounjaro.

Oct 3 (Reuters) – Eli Lilly and Co  will buy cancer therapy developer Point Biopharma Global  for $1.4 billion, the companies said on Tuesday.

 Eli Lilly’s diabetes drug Mounjaro has gained the backing of Britain’s healthcare cost-effectiveness watchdog, which said it would be a good option for patients with poorly controlled type 2 diabetes.

Eli Lilly stock was flying on Tuesday after the drugmaker recorded quarterly profit and revenue well ahead of Wall Street’s expectations. Sales of obesity drugs are delivering the goods.

July 27 (Reuters) – Eli Lilly (LLY.N) said on Thursday its experimental obesity drug met the main goals in two late-stage studies, with the drug helping patients reduce 26.6% weight on average in one of the studies following intensive lifestyle changes.

Eli Lilly’s experimental drug helped patients lose up to 24% of their weight after almost a year, the highest reduction seen in the obesity treatment space to date, according to new mid-stage clinical trial results released Monday.

Eli Lilly has agreed to buy DICE Therapeutics in a $2.4 billion cash deal that reflects Lilly’s ambitions in immunology, a hot market where the company has lagged behind its coompetitors.